{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:14:14Z","timestamp":1760166854363,"version":"build-2065373602"},"reference-count":41,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Uveal melanoma (UM) is a primary neoplasm of the eye arising from the melanocytes residing in the iris, ciliary body or choroid. It is the most frequent intraocular malignancy and often determines metastases at distant sites, with a peculiar tropism for the liver. Metastatic UM has a poor prognosis, as any treatment affects the natural course of this fatal disease. Herein, we report a case of a UM metastatic to the liver in a 54 year-old female patient, initially treated with nivolumab without success. The patient was then scheduled for selective internal radiation therapy (SIRT) while continuing immunotherapy. This combination led to a complete and durable response and the patient is currently free of disease, two years after the diagnosis of the hepatic metastases. The association between SIRT and immunotherapy (IT) has very promising perspectives for metastatic UM, especially considering the disappointing or contradictory results of classic chemotherapies, IT alone and targeted therapies. Furthermore, this combination has been shown to have a good security profile. However, further studies are needed to confirm the efficacy of associating SIRT and IT and to clarify some unsolved problems, such as the timing of administration of these two therapies.<\/jats:p>","DOI":"10.3390\/life11070692","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T10:13:42Z","timestamp":1626257622000},"page":"692","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-Term Maintained Response to Selective Internal Radiation Therapy in an Oligometastatic Uveal Melanoma Patient Treated with Concomitant Anti-PD-1 Therapy"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3795-3190","authenticated-orcid":false,"given":"Ilaria","family":"Proietti","sequence":"first","affiliation":[{"name":"Dermatology Unit \u201cDaniele Innocenzi\u201d, \u201cA. Fiorini\u201d Hospital, Via Firenze, 1, 04019 Terracina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nevena","family":"Skroza","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u201cDaniele Innocenzi\u201d, \u201cA. Fiorini\u201d Hospital, Via Firenze, 1, 04019 Terracina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4423-5496","authenticated-orcid":false,"given":"Luca","family":"Filippi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, \u201cSanta Maria Goretti\u201d Hospital, Via Antonio Canova, 04100 Latina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Bernardini","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u201cDaniele Innocenzi\u201d, \u201cA. Fiorini\u201d Hospital, Via Firenze, 1, 04019 Terracina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Mambrin","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u201cDaniele Innocenzi\u201d, \u201cA. Fiorini\u201d Hospital, Via Firenze, 1, 04019 Terracina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ersilia","family":"Tolino","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u201cDaniele Innocenzi\u201d, \u201cA. Fiorini\u201d Hospital, Via Firenze, 1, 04019 Terracina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Rossi","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u201cDaniele Innocenzi\u201d, \u201cA. Fiorini\u201d Hospital, Via Firenze, 1, 04019 Terracina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Marchesiello","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u201cDaniele Innocenzi\u201d, \u201cA. Fiorini\u201d Hospital, Via Firenze, 1, 04019 Terracina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Marraffa","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u201cDaniele Innocenzi\u201d, \u201cA. Fiorini\u201d Hospital, Via Firenze, 1, 04019 Terracina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Volpe","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u201cDaniele Innocenzi\u201d, \u201cA. Fiorini\u201d Hospital, Via Firenze, 1, 04019 Terracina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oreste","family":"Bagni","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, \u201cSanta Maria Goretti\u201d Hospital, Via Antonio Canova, 04100 Latina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concetta","family":"Potenza","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u201cDaniele Innocenzi\u201d, \u201cA. Fiorini\u201d Hospital, Via Firenze, 1, 04019 Terracina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Pfeffer, U. (2019). Uveal Melanoma. Cancers, 11.","DOI":"10.3390\/cancers11121986"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","article-title":"Metastatic disease from uveal melanoma: Treatment options and future prospects","volume":"101","author":"Carvajal","year":"2016","journal-title":"Br. J. Ophthalmol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/OPTH.S89591","article-title":"Uveal melanoma: Epidemiology, etiology, and treatment of primary disease","volume":"11","author":"Krantz","year":"2017","journal-title":"Clin. Ophthalmol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40487-018-0056-8","article-title":"Uveal Melanoma: A Review of the Literature","volume":"6","author":"Singh","year":"2018","journal-title":"Oncol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Rodriguez-Vidal, C., Fernandez-Diaz, D., Fernandez-Marta, B., Lago-Baameiro, N., Pardo, M., Silva, P., Paniagua, L., Blanco-Teijeiro, M.J., Pi\u00f1eiro, A., and Bande, M. (2020). Treatment of Metastatic Uveal Melanoma: Systematic Review. Cancers, 12.","DOI":"10.3390\/cancers12092557"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Schank, T.E., and Hassel, J.C. (2019). Immunotherapies for the Treatment of Uveal Melanoma\u2014History and Future. Cancers, 11.","DOI":"10.3390\/cancers11081048"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"350","DOI":"10.2967\/jnumed.119.230870","article-title":"First-Line Selective Internal Radiation Therapy in Patients with Uveal Melanoma Metastatic to the Liver","volume":"61","author":"Ponti","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/ICU.0000000000000761","article-title":"Radiation therapy for uveal melanoma: A review of treatment methods available in 2021","volume":"32","author":"Reichstein","year":"2021","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/pcmr.12507","article-title":"Analysis of monosomy-3 in immunomagnetically isolated circulating melanoma cells in uveal melanoma patients","volume":"29","author":"Tura","year":"2016","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1167\/iovs.14-14512","article-title":"Identification of Circulating Melanoma Cells in Uveal Melanoma Patients by Dual-Marker Immunoenrichment","volume":"55","author":"Tura","year":"2014","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000328283","article-title":"Prognostic relevance of circulating tumor cells in metastatic uveal melanoma","volume":"80","author":"Schuster","year":"2011","journal-title":"Oncology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1158\/1078-0432.CCR-06-2329","article-title":"Circulating Tumor Cells as Prognostic Factor for Distant Metastases and Survival in Patients with Primary Uveal Melanoma","volume":"13","author":"Schuster","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IIO.0000000000000160","article-title":"Micrometastatic dormancy in uveal melanoma: A comprehensive review of the evidence, mechanisms, and implications for future adjuvant therapies","volume":"57","author":"Nichols","year":"2017","journal-title":"Int. Ophthalmol. Clin."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.2147\/OPTH.S28863","article-title":"Current and emerging treatment options for uveal melanoma","volume":"7","author":"Pereira","year":"2013","journal-title":"Clin. Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1093\/annonc\/mdt376","article-title":"Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma","volume":"24","author":"Maio","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"9033","DOI":"10.1200\/jco.2014.32.15_suppl.9033","article-title":"Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial","volume":"32","author":"Rodriguez","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Zimmer, L., Vaubel, J., Mohr, P., Hauschild, A., Utikal, J., Simon, J., Garbe, C., Herbst, R., Enk, A., and K\u00e4mpgen, E. (2015). Phase II DeCOG-study of ipilimumab in pretreated and treatment-na\u00efve patients with metastatic uveal melanoma. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0118564"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1200\/jco.2015.33.15_suppl.9010","article-title":"The use of pembrolizumab for the treatment of metastatic uveal melanoma","volume":"33","author":"Kottschade","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1001\/jama.2014.6096","article-title":"Effect of selumetinib vs. chemotherapy on progression-free survival in uveal melanoma: A randomized clinical trial","volume":"311","author":"Carvajal","year":"2014","journal-title":"JAMA"},{"key":"ref_20","unstructured":"Carvajal, R.D., Piperno-Neumann, S., and Kapiteijn, E. (2015). SUMIT: Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Selumetinib in Combination with Dacarbazine in Patients with Metastatic Uveal Melanoma, Society for Melanoma Research Congress."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1470-2045(12)70269-3","article-title":"Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: A phase 1 dose-escalation trial","volume":"13","author":"Falchook","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00008390-200508000-00003","article-title":"Immunohistochemical expression of phospho-Akt in uveal melanoma","volume":"15","author":"Saraiva","year":"2005","journal-title":"Melanoma Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1158\/1535-7163.MCT-12-1020","article-title":"Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death","volume":"12","author":"Ambrosini","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_24","first-page":"1","article-title":"Immunostimulatory effects of radiotherapy for local and systemic control of melanoma: A review","volume":"21","author":"Takahashi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.humpath.2017.06.005","article-title":"Inflammatory cell infiltrates in advanced metastatic uveal melanoma","volume":"66","author":"Krishna","year":"2017","journal-title":"Hum. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/j.jvir.2018.12.289","article-title":"03:18 PM Abstract No. 230 Predictors of overall and progression-free survival in patients with ocular melanoma metastatic to the liver undergoing Y90 radioembolization: A 15-year single-institution experience","volume":"30","author":"Levey","year":"2019","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jvir.2020.04.029","article-title":"Safety and Effectiveness of Yttrium-90 Radioembolization around the Time of Immune Checkpoint Inhibitors for Unresectable Hepatic Metastases","volume":"31","author":"Ruohoniemi","year":"2020","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jvir.2018.04.030","article-title":"Combined Effects of Yttrium-90 Transarterial Radio-embolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series","volume":"29","author":"Zheng","year":"2018","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_29","first-page":"1","article-title":"A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases","volume":"2","author":"Arulananda","year":"2019","journal-title":"Cancer Rep."},{"key":"ref_30","first-page":"204798161557041","article-title":"A single-center experience in radioembolization as salvage therapy of hepatic metastases of uveal melanoma","volume":"4","author":"Schelhorn","year":"2015","journal-title":"Acta Radiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cncr.33424","article-title":"Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety","volume":"127","author":"Williamson","year":"2021","journal-title":"Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jvir.2013.08.021","article-title":"Quantitative dosimetry for yttrium-90 radionuclide therapy: Tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma","volume":"25","author":"Eaton","year":"2014","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s00259-015-3178-3","article-title":"Molecular response assessed by 68Ga-DOTANOC and survival after 90Y microsphere therapy in patients with liver metastases from neuroendocrine tumours","volume":"43","author":"Filippi","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jvir.2020.09.014","article-title":"Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety Analysis","volume":"32","author":"Leppelmann","year":"2021","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2217\/fon-2017-0443","article-title":"Yttrium-90 resin microspheres and their use in the treatment of intrahepatic cholangiocarcinoma","volume":"14","author":"Filippi","year":"2018","journal-title":"Future Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/cncr.23339","article-title":"Liver disease induced by radioembolization of liver tumors: Description and possible risk factors","volume":"112","author":"Sangro","year":"2008","journal-title":"Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/MEG.0000000000000772","article-title":"Radioembolization-induced liver disease: A systematic review","volume":"29","author":"Braat","year":"2017","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.ijrobp.2008.10.005","article-title":"Treatment Parameters and Outcome in 680 Treatments of Internal Radiation With Resin 90Y-Microspheres for Unresectable Hepatic Tumors","volume":"74","author":"Kennedy","year":"2009","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00270-011-0295-7","article-title":"Hepatic Toxicity After Radioembolization of the Liver Using 90Y-Microspheres: Sequential Lobar Versus Whole Liver Approach","volume":"35","author":"Seidensticker","year":"2012","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"20200752","DOI":"10.1259\/bjr.20200752","article-title":"Safety and efficacy of repeat Y90 radioembolization to the same hepatic arterial territory","volume":"94","author":"Badar","year":"2021","journal-title":"Br. J. Radiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.jvir.2019.08.030","article-title":"Re: Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma","volume":"30","author":"Walrand","year":"2019","journal-title":"J. Vasc. Interv. Radiol."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/11\/7\/692\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:30:27Z","timestamp":1760164227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/11\/7\/692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["life11070692"],"URL":"https:\/\/doi.org\/10.3390\/life11070692","relation":{},"ISSN":["2075-1729"],"issn-type":[{"type":"electronic","value":"2075-1729"}],"subject":[],"published":{"date-parts":[[2021,7,14]]}}}